{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:32:45Z","timestamp":1762176765351},"reference-count":21,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T00:00:00Z","timestamp":1409184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gastric cancer (<jats:styled-content style=\"fixed-case\">GC<\/jats:styled-content>) continues to be an important health threat as the third leading cause of cancer related death in both sexes worldwide. In a recent analysis, the mortality trends for the time period from 1980 till 2011 were significantly downward in all countries, but the declines in the <jats:styled-content style=\"fixed-case\">USA<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> EU<\/jats:styled-content> and several other major countries were of low magnitude when compared with the past. Furthermore, the relative contribution of cardia cancers compared with noncardia cancers increased among countries with higher <jats:styled-content style=\"fixed-case\">GC<\/jats:styled-content> rates. With respect to preneoplastic changes of the gastric mucosa, a large population\u2010based study suggests that <jats:italic>Helicobacter pylori<\/jats:italic> infection and antigastric parietal cell antibodies\u2010mediated autoimmune response might, for the most part, be independent and follow distinct pathways rather than causally related pathways leading to chronic atrophic gastritis. A large prospective, randomized, open\u2010label Korean trial questioned the role of <jats:italic>H.\u00a0pylori<\/jats:italic> eradication for the prevention of metachronous lesions after endoscopic resection of early <jats:styled-content style=\"fixed-case\">GC<\/jats:styled-content>. A review of 1258 Japanese cases undergoing curative endoscopic submucosa dissection for early <jats:styled-content style=\"fixed-case\">GC<\/jats:styled-content> showed that scheduled follow\u2010up endoscopy is mandatory for detecting metachronous lesions at an early stage, where they can be treated by endoscopic resection. Ramucirumab, a vascular endothelial growth factor receptor\u20102 antagonist, is the first biological treatment that provides survival benefits to patients with advanced <jats:styled-content style=\"fixed-case\">GC<\/jats:styled-content> in progress after first\u2010line chemotherapy. The target agent rilotumumab is currently being evaluated in patients with advanced <jats:styled-content style=\"fixed-case\">GC<\/jats:styled-content> overexpressing the <jats:styled-content style=\"fixed-case\">HGF<\/jats:styled-content>\/c\u2010<jats:styled-content style=\"fixed-case\">MET<\/jats:styled-content> signaling pathway. In the near future, ipilimumab and nivolumab, two immunostimulatory monoclonal antibodies with antineoplastic effects, might offer new therapeutic options for patients with advanced <jats:styled-content style=\"fixed-case\">GC<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/hel.12164","type":"journal-article","created":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T02:47:04Z","timestamp":1409280424000},"page":"32-37","source":"Crossref","is-referenced-by-count":16,"title":["Gastric Cancer\u2014Epidemiologic and Clinical Aspects"],"prefix":"10.1111","volume":"19","author":[{"given":"Marino","family":"Venerito","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases Otto\u2010von\u2010Guericke University Hospital Magdeburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Nardone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Department of Clinical Medicine and Surgery University Federico II of Naples Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Selgrad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases Otto\u2010von\u2010Guericke University Hospital Magdeburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros","family":"Rokkas","sequence":"additional","affiliation":[{"name":"Gastroenterology Clinic Henry Dunant Hospital Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases Otto\u2010von\u2010Guericke University Hospital Magdeburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v4.i7.156"},{"key":"e_1_2_8_3_1","volume-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]","author":"Ferlay J","year":"2013"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.11.001"},{"key":"e_1_2_8_5_1","volume-title":"TNM Classification of Malignant Tumours","author":"Sobin LH","year":"2009"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70546-1"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.01.029"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt108"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-1343"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61159-9"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2011.08.030"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.404"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.09.057"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301647"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.3_suppl.lba7","article-title":"RAINBOW: a global, phase III, randomized, double\u2010blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first\u2010line platinum\u2010 and fluoropyrimidine\u2010containing combination therapy rainbow IMCL CP12\u20100922 (I4T\u2010IE\u2010JVBE). Presented at the 2014 Gastrointestinal Cancers Symposium","volume":"32","author":"Wilke H","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70096-2"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70102-5"},{"key":"e_1_2_8_19_1","unstructured":"A Phase 3 Multicenter Randomized Double\u2010Blind Placebo Controlled Study of Rilotumumab (AMG 102) With Epirubicin Cisplatin and Capecitabine (ECX) as First\u2010line Therapy in Advanced MET\u2010Positive Gastric or Gastroesophageal Junction Adenocarcinoma. ClinicalTrials.gov Identifier: NCT01697072 [WWW document]. URL:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01697072"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S57550"},{"key":"e_1_2_8_21_1","unstructured":"A Randomized Open\u2010label Two\u2010arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First\u2010line Chemotherapy in Subjects With Unresectable Locally Advanced\/Metastatic Gastric or Gastro\u2010esophageal Junction Cancer. ClinicalTrials.gov Identifier: NCT01585987. [WWW document]. URL:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01585987"},{"key":"e_1_2_8_22_1","unstructured":"A Phase 1\/2 Open\u2010label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors. ClinicalTrials.gov Identifier: NCT01928394. [WWW document]. URL:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01928394"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhel.12164","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hel.12164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T13:25:46Z","timestamp":1694438746000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hel.12164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,28]]},"references-count":21,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/hel.12164"],"URL":"https:\/\/doi.org\/10.1111\/hel.12164","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,28]]}}}